Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00107289
Status:
RECRUITING
Last Update Posted:
2024-03-12
First Post:
2005-04-05
Brief Title:
Iodine I 131 Metaiodobenzylguanidine in Treating Patients with Recurrent Progressive or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Open Access Protocol of Targeted Radiotherapy with I-metaiodobenzylguanidine I-MIBG in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma malignant pheochromocytoma and malignant paraganglioma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MSKCC-04148 | None | None | None |